Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "autoimmune"

124 News Found

Sandoz enters agreement for oncology biosimilar medicine bevacizumab
Drug Approval | September 09, 2021

Sandoz enters agreement for oncology biosimilar medicine bevacizumab

Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems

Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar
Biotech | August 20, 2021

Enzene Biosciences obtains DCGI approval for Romiplostim biosimilar

It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)

Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
Biotech | August 10, 2021

Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings

A veteran in cell therapy and oncology commercialisation

Union Minister Sonowal promises AIIA of establishing a Bio-bank in Ayurveda
Events | August 09, 2021

Union Minister Sonowal promises AIIA of establishing a Bio-bank in Ayurveda

All India Institute of Ayurveda hosts ministers and showcase their achievements

Latest Stories

Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation

HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging